Related regulators of N6‐methyladenosine (m6A), 5‐methylcytosine (m5C) and N7‐methylguanosine (m7G) are involved in the signalling pathways of drug resistance during tumour treatment
The related regulators of N6‐methyladenosine (m6A), 5‐methylcytosine (m5C) and N7‐methylguanosine (m7G) are involved in the signalling pathways of drug resistance during tumour treatment. The JAK/STAT3 signalling pathway is the downstream pathway of cytokine signalling, which regulates cell development, differentiation, proliferation, apoptosis, etc. It not only participates in the regulation of normal physiological processes, but also plays an important role in the occurrence and development of tumours. PI3K/AKT signalling pathway is also one of the important signal transduction pathways in cells, and its main role is to inhibit cell apoptosis and promote proliferation. PI3K/AKT signalling pathway is abnormally regulated in a variety of malignant tumours, and then promotes tumour cell proliferation and neovascularisation, inhibits cell apoptosis, and is closely related to tumour invasion and metastasis
Publication
RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy (2024) Huanxiang Chen, et al. Clin Transl Med. 2024 Apr;14(4). Figure: F2.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | DDP | DDP | ncbigene_synonym | TIMM8A | 1678 |
| Homo sapiens | Primates | AKT | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | AKT | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | JAK2 | JAK2 | ncbigene_symbol | JAK2 | 3717 |
| Homo sapiens | Primates | JANCZ/STAT3+ | STAT3 | ncbigene_symbol | STAT3 | 6774 |
| Homo sapiens | Primates | WTAP | WTAP | ncbigene_symbol | WTAP | 9589 |
| Homo sapiens | Primates | METTL14 | METTL14 | ncbigene_symbol | METTL14 | 57721 |
| Homo sapiens | Primates | alkbh5 | ALKBH5 | ncbigene_symbol | ALKBH5 | 54890 |
| Homo sapiens | Primates | HOXA10 | HOXA10 | ncbigene_symbol | HOXA10 | 3206 |
| Homo sapiens | Primates | MANA | MANA | ncbigene_synonym | MAN2C1 | 4123 |
| Homo sapiens | Primates | CCNB | CCNB | ncbigene_synonym | CCNB1 | 891 |
| Homo sapiens | Primates | DOP | DOP | ncbigene_synonym | OPRD1 | 4985 |
| Homo sapiens | Primates | (MMP3) | MMP3 | ncbigene_symbol | MMP3 | 4314 |
| Homo sapiens | Primates | MMP10 | MMP10 | ncbigene_symbol | MMP10 | 4319 |
| Homo sapiens | Primates | NMR | NMR | ncbigene_synonym | LINC01672 | 100505887 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Nucleus | nucleus | nucleus | chebi:33252 | |
| Sunitinib | sunitinib | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | chebi:38940 | |
| Sorafenib | sorafenib | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide | chebi:50924 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|